Private Placement

Luxury brand Perfect Moment lands a $12M financing package, including an equity deal at a 75% premium, signaling a major vote of confidence for its China expansion.

With new leadership and better finances, Star Diamond pushes its massive diamond project forward, but funding challenges and a volatile market loom large.

As Texas ranks last for mental health access, a new South Austin clinic offers an integrated care model to combat long waits and fragmented treatment.

A new partnership aims to disrupt the vacation rental market by eliminating host fees, putting pressure on industry giants like Airbnb and Vrbo.

Kenon Holdings announces a $200M dividend fueled by its OPC Energy unit, whose profits soared in 2025, as it completes its strategic exit from shipping.

Birchtech launches its SEA-IX™ resin line, aiming to disrupt a consolidated market and bolster supply chains for critical nuclear and water utilities.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A Georgia firm's painless patch technology earns top honors, promising to revolutionize medicine delivery and solve critical global health challenges.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

As millions grapple with Cannabis Use Disorder, a small biotech's lead drug enters Phase 3 trials, promising the first-ever FDA-approved treatment.

A major partnership is set to unlock Yukon's Stikine Terrane, as Agnico Eagle invests millions in Cascadia Minerals to fund a massive exploration push.

As Aqua Metals reports its 2025 financials, investors seek proof its recycling tech can deliver amid market volatility and new strategic partnerships.

After its pivotal trial for ersodetug missed its primary endpoint, Rezolute gets a rare nod from the FDA to submit full data, igniting new hope.

Amid soaring healthcare costs, The Difference Card appoints sales directors for the Southeast and West, signaling an aggressive push to expand its reach.

A landmark partnership is scaling a 'one-drug, many-diseases' therapy, revealing how logistics, not just labs, are key to the future of medicine.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.